WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up Following Earnings Beat

Posted by Brian Himes on Oct 27th, 2026

WAVE Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $3.21, but opened at $3.55. WAVE Life Sciences shares last traded at $3.3450, with a volume of 331,315 shares changing hands.

The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $13.16 million for the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. LADENBURG THALM/SH SH initiated coverage on shares of WAVE Life Sciences in a research report on Thursday, October 1st. They set a “buy” rating and a $10.00 target price for the company. Mizuho decreased their price objective on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Zacks Research cut shares of WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Thursday, October 15th. Finally, Wedbush set a $13.00 price target on WAVE Life Sciences in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, WAVE Life Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $21.53.

View Our Latest Stock Analysis on WVE

Insiders Place Their Bets

In other news, Director Heidi L. Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company’s stock, valued at $270,029.30. The trade was a 13.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 23,564 shares of company stock valued at $132,476. Insiders own 24.34% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Readystate Asset Management LP purchased a new stake in WAVE Life Sciences in the 2nd quarter worth $27,465,000. Squarepoint Ops LLC boosted its position in shares of WAVE Life Sciences by 68.0% during the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock valued at $14,766,000 after acquiring an additional 1,029,052 shares during the last quarter. Pictet Asset Management Holding SA increased its position in WAVE Life Sciences by 42.6% in the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after purchasing an additional 343,226 shares during the last quarter. Renaissance Technologies LLC increased its position in WAVE Life Sciences by 152.6% in the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after purchasing an additional 360,800 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in WAVE Life Sciences by 12.4% during the first quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company’s stock valued at $2,619,000 after purchasing an additional 39,759 shares in the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

WAVE Life Sciences Price Performance

The firm has a market cap of $655.78 million, a P/E ratio of -3.05 and a beta of -1.43. The company’s 50-day simple moving average is $4.20 and its 200 day simple moving average is $7.71.

WAVE Life Sciences Company Profile

(Get Free Report)

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.